Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2266 to 2280 of 7710 results

  1. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development [GID-TA11117] Expected publication date: TBC

  2. Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]

    Awaiting development [GID-TA11428] Expected publication date: TBC

  3. Gambling-related harms: identification, assessment and management

    In development [GID-NG10210] Expected publication date: TBC

  4. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: TBC

  5. Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain (MTG41)

    Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.

  6. UrgoStart for treating diabetic foot ulcers and leg ulcers (MTG42)

    Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers.

  7. PICO negative pressure wound dressings for closed surgical incisions (MTG43)

    Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions.

  8. Endocuff Vision for assisting visualisation during colonoscopy (MTG45)

    Evidence-based recommendations on Endocuff Vision for assisting visualisation during colonoscopy.

  9. gammaCore for cluster headache (MTG46)

    Evidence-based recommendations on gammaCore for cluster headache.

  10. Tegaderm CHG securement dressing for vascular access sites in critically ill adults (MTG25)

    Evidence-based recommendations on The 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites.

  11. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development [GID-TA11454] Expected publication date: 16 July 2025

  12. Tiratricol for treating Allan–Herndon–Dudley syndrome ID6217

    Awaiting development [GID-TA11192] Expected publication date: TBC

  13. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    Awaiting development [GID-TA11303] Expected publication date: TBC

  14. Nemolizumab for treating prurigo nodularis [ID6451]

    In development [GID-TA11566] Expected publication date: 21 May 2025